Device Warning Letter Pilot Discontinued; OCC Review Cited As Alternative
This article was originally published in The Gray Sheet
Executive Summary
The Medical Device Initiative Grassroots Task Force will be briefed regularly on FDA's warning and untitled letter activities, following the agency's decision to end its device center warning letter pilot program
You may also be interested in...
FDA To Release Warning Letter Responses, Sans Some Related Materials
A six-month pilot program to post FDA warning letter responses on the agency's website, at the recipient's request, will elevate the profile of companies seeking to allay compliance concerns
FDA To Release Warning Letter Responses, Sans Some Related Materials
A six-month pilot program to post FDA warning letter responses on the agency's website, at the recipient's request, will elevate the profile of companies seeking to allay compliance concerns
RAPS In Brief
PMA ABCs: Action definitions and procedures guidance will explain terms related to all PMA decisions listed under the performance goals of MDUFMA, ranging from "approval" and "approvable pending GMP" to "denial" and "abandonment," CDRH Premarket Approval Section Director Thinh Nguyen reports at the Regulatory Affairs Professionals Society medical device conference in San Francisco March 4. One of six PMA-related guidances under development, the document will provide criteria for decision letters and explain how certain actions affect FDA's review clock and performance goals...